Search Results
Your search for ,WHo matches 20203 pages
Showing 15651 - 15700Bevacizumab plus Chemotherapy after Progression of Metastatic Colorectal Cancer on First-line Therapy Including Bevacizumab
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On January 23, 2013, bevacizumab (Avastin) was approved...
SIDEBAR: Beta-adrenergic Signaling Pathway
The take-home message from this study is that in this large group of patients, we have found that beta-blocker intake during radiation therapy for non–small cell lung cancer (NSCLC) is associated with improved survival and reduced rates of tumor spread, even when controlling for a large number of...
More Brief Reports from ASH, Including New Data in Leukemia, Lymphoma, and Myelodysplastic Syndrome
At the 54th Annual Meeting of the American Society of Hematology (ASH), held in Atlanta, nearly 5,000 abstracts were presented in oral sessions and posters. As part of our ongoing comprehensive coverage from the meeting, here are several more studies of note. New Targets in Acute Myeloid Leukemia...
Global Women’s Cancer Summit: Collaboration Aims to Reduce Breast, Cervical Cancers
World leaders from governments, cancer organizations, and the private sector joined together recently for the first Global Women’s Cancer Summit to address the challenge of reducing the global burden of women’s cancers. The summit was hosted by Susan G. Komen for the Cure and underwritten by GE...
Expert Point of View: David J. Kuter, MD, PhD
David J. Kuter, MD, PhD, Professor of Medicine, Harvard Medical School, and Director of the Center for Hematology at Massachusetts General Hospital, Boston, commented on the findings for The ASCO Post. “TOPPS is a good attempt to address whether transfusions are helpful as prophylaxis in patients...
No Rationale for Eliminating Prophylactic Platelet Transfusions in Patients with Hematologic Malignancies
Prophylactic platelet transfusions should remain the standard of care for many patients with hematologic malignancies who are thrombocytopenic during intensive treatment or stem cell transplant, investigators of the TOPPS trial (noninferiority Trial Of Prophylactic Platelet transfusionS)...
A New Donor Shines with Conquer Cancer Foundation
To support all of our valuable programs for patients and physicians, the Conquer Cancer Foundation of the American Society of Clinical Oncology partners with organizations of every size and scale, and every partnership has a lasting impact. Recently, the Foundation began working with a new...
Expert Point of View: Laura van't Veer, PhD
Laura van’t Veer, PhD, Director of the Specialized Programs of Research Excellence (SPORE) of the University of California, San Francisco, commented on the meta-analysis. She said the study confirms that a pathologic complete response in the neoadjuvant setting is generally meaningful as it clearly ...
Pathologic Complete Response Yields Long-term Benefits in Meta-analysis
Breast cancer patients who achieve a pathologic complete response to neoadjuvant therapy have more favorable outcomes than those who do not, according to a meta-analysis of neoadjuvant trials presented at the 2012 San Antonio Breast Cancer Symposium.1 Patients who achieved a pathologic complete...
Expert Point of View: Sandra Swain, MD, FACP
Sandra Swain, MD, FACP, Medical Director of the Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, moderated the San Antonio session where the dose-dense chemotherapy studies were presented, and commented on the findings of the two studies. iddETC Trial With regard...
Dose-dense Chemotherapy in Breast Cancer: Epirubicin-based Regimens Studied in German and UK Trials
In the treatment of early breast cancer, dose-dense regimens (given every 2 weeks) have proven superior to conventionally dosed chemotherapy (given every 3 weeks), but data on long-term survival are lacking. Two studies presented at the San Antonio Breast Cancer Symposium evaluated the benefit of...
Final 'Joint Analysis' Confirms Life-saving Benefit of Trastuzumab in Patients with HER2-positive Early Breast Cancer
In the final planned joint analysis of overall survival from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 and North Central Cancer Treatment Group (NCCTG) N9831 trials, the addition of trastuzumab (Herceptin) to paclitaxel following doxorubicin/cyclophosphamide (AC) reduced...
The Challenges and Rewards of Neuro-oncology
Despite the extremely difficult clinical challenges posed by brain tumors, mortality rates in this disease have decreased somewhat over the past several decades due, in part, to advances in surgical techniques and therapies. The ASCO Post recently discussed contemporary issues in neuro-oncology...
Expert Point of View: Axel Grothey, MD and Eric Van Cutsem, MD, PhD
Two gastrointestinal cancer experts commented on the findings in interviews with The ASCO Post. Axel Grothey, MD, Professor of Oncology at the Mayo Clinic, Rochester, Minnesota, noted, “The PEAK and SPIRITT trial were decently designed, decently powered randomized phase II trials, and the results...
Outcomes Comparable for Panitumumab and Bevacizumab in Metastatic Colorectal Cancer
In patients with KRAS wild-type metastatic colorectal cancer, outcomes were comparable whether patients received the epidermal growth factor receptor (EGFR) inhibitor panitumumab (Vectibix) or the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin). This was shown both in the...
FDA Approves Pomalidomide for Advanced Multiple Myeloma
The FDA approved pomalidomide (Pomalyst) an oral immunomodulatory agent, to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Pomalidomide is intended for patients who have received at least two prior therapies, including lenalidomide...
On Radiation and Cancer Risk
We owe our life to radiation. The universe was created in a thermonuclear explosion, and continued existence of life on Earth depends on plants using chlorophyll to capture light energy emitted by the sun (and exploding supernovas) and converting it into chemical energy, with the subsequent...
Study Finds Young Cancer Survivors Often Skip Checkups
Athough the majority of the more than 69,000 adolescents and young adults (AYAs) diagnosed with cancer each year will survive their disease, many of them will experience interruptions in their education and a derailment in their career tract, curtailing their lifetime earning potential and reducing ...
Expert Point of View: Jordan D. Berlin, MD
Jordan D. Berlin, MD, Ingram Professor of Cancer Research and Clinical Director of the GI Oncology Program at Vanderbilt-Ingram Cancer Center, Nashville, commented on the findings of TRIBE. “This study is outstanding, and while we don’t have overall survival data yet the findings suggest that we...
Sequestration Will Have Shattering Impact on Entire U.S. Cancer Enterprise
March 1 marked the beginning of sequestration, the unprecedented automatic budget cuts that immediately take effect across the federal government—after months of futile negotiations by the President and Congress. Sequestration will have a shattering impact on the entire cancer enterprise in the...
Large Epidemiologic Studies Re-examine Hazards of Smoking
“Smokers lose at least one decade of life expectancy, as compared with those who have never smoked,” and the increased risk of death from cigarettes smoking “are now nearly identical for men and women,” according to two separate studies published online by TheNew England Journal of Medicine. One...
Older Patients Do Better with Hematopoietic Transplants from Siblings of Similar Age than from Younger but Unrelated Donors
Patients ≥ 50 years old with leukemia/lymphoma are increasingly undergoing allogeneic hematopoietic cell transplants, raising questions about whether they might have better outcomes with transplants from younger allele-level 8/8 human leukocyte antigen (HLA)-matched unrelated donors than from...
Trametinib Shows Activity in Previously Treated but BRAF Inhibitor–naive BRAF-mutant Melanoma
In a multicenter phase II study, trametinib showed “significant clinical activity” in a cohort of BRAF inhibitor–naive patients with BRAF-mutant cutaneous melanoma previously treated with chemotherapy and/or immunotherapy. Only minimal clinical activity, however, was observed among a cohort of...
SIDEBAR: Ask Patients about Their Smoking Status
“Receiving a cancer diagnosis represents a ‘teachable moment’ for delivering smoking cessation and relapse prevention interventions,” concluded a study in the journal Cancer1 about smoking relapse in patients with thoracic cancer or head and neck cancer. Previous research by two of the study’s...
Patients with Cancer Need to Know That It Is Never Too Late to Quit Smoking
In the News focuses on media reports that your patients may have questions about at their next visit. This continuing column will provide summaries of articles in the popular press that may prompt such questions, as well as comments from colleagues in the field. Patients with head and neck or lung...
Fitness: Can Exercise Lengthen Survival in Patients with Cancer?
Regular physical activity has long been associated with decreased risk of disease, including many types of cancer. Such benefits may translate into increased life expectancy of up to 4.5 years, with even the lowest levels of activity providing some survival advantage.1 Most strikingly, however,...
My Life Will Never Be Normal
After being diagnosed with stage II invasive ductal carcinoma in my right breast in 2004, I did an Internet search to learn more about my treatment options so I could be prepared when I met with my oncologist to discuss my treatment plan. I was especially interested in therapies that would be...
Zora Brown, Prominent Cancer Research Advocate, Dies at 63
The American Association for Cancer Research (AACR) reported with sadness the loss of Zora Brown, a trustee for the AACR Foundation for the Prevention and Cure of Cancer, a breast and ovarian cancer survivor, and a pioneering advocate for cancer research and breast cancer awareness among...
Focus on the Medical Oncology Association of Southern California
For more than 2 decades, the guiding principle of the Medical Oncology Association of Southern California (MOASC) has been to ensure the continuation of the private practice of medical oncology and to provide the highest quality care to cancer patients. Founded in 1990, MOASC is the largest...
Study Shows New Approach Connecting Smokers to Quit Lines Increases Smoking Cessation Treatment Enrollment
Self-identified smokers directly connected to a tobacco cessation quit line are 13 times more likely to enroll in a treatment program as compared to smokers who are handed a quit line referral card and encouraged to call on their own, according to a new study published online in JAMA Internal...
IBM's Watson Goes Through Basic Training in Oncology
While IBM’s Watson supercomputer may have defeated two former champions on the TV game show Jeopardy! 2 years ago, it is now facing its greatest challenge yet: deciphering huge amounts of scientific data and interpreting clinical information to help oncologists make personalized evidence-based...
Survey Shows Public's Knowledge of Cancer Progress Is Rising, But Myths Persist
People are more optimistic today about their chances of surviving cancer, according to findings from a new international survey commissioned by Lilly Oncology. The phone survey of 4,341 individuals (including people in the general population, cancer survivors, and caregivers) in six countries (the...
Jane Cooke Wright, MD, ASCO Cofounder, Dies at 93
The practice of oncology advances incrementally; each step forward, no matter how painfully small at times, leads to the next. The oncology community readily offers tribute to predecessors in the field who took those first steps into the uncharted regions of cancer care, without which today’s...
Analysis Shows No 10-year Survival Advantage in Patients with Ovarian Cancer and BRCA1 or BRCA2 Mutations
Several studies have suggested that short-term overall survival for women with ovarian cancer and BRCA1 or BRCA2 mutations is better than that in patients without such mutations. Indeed, a recent report by Kelly L. Bolton, PhD, and colleagues indicated that 5-year overall survival was 36% for...
Medication Safety at Home
A risk assessment to identify how errors occur when oral chemotherapies are used by pediatric patients at home (and to propose risk-reduction strategies) relied on input from those primarily in charge of oral chemotherapy use at home—the parents. A total of 18 parents were recruited at three...
Preparing for the Next Superstorm: Protecting Patients during Natural Disasters
When Hurricane Sandy slammed into the East Coast last October, the magnitude of devastation it left in its wake exceeded even the most dire predictions. Eighty mile per hour winds and record storm surges destroyed antiquated electrical grids and flooded subway stations, leaving much of New York...
FDA Approves Regorafenib for Advanced Gastrointestinal Stromal Tumors
The FDA has expanded the approved use of regorafenib (Stivarga) to treat patients with metastatic or unresectable gastrointestinal stromal tumors (GIST) that no longer respond to treatment with imatinib (Gleevec) or sunitinib (Sutent). Regorafenib, a multikinase inhibitor, blocks several enzymes...
FOXP3 Expression Linked to Better Survival with Adjuvant Anthracycline Not Followed by Taxane in Breast Cancer
The French UNICANCER-PACS 01 trial compared six cycles of anthracycline-based adjuvant therapy with FEC (epirubicin, cyclophosphamide, fluorouracil; FEC6) vs three cycles of FEC followed by three cycles of docetaxel (FEC/docetaxel) in patients with node-positive primary breast cancer. After...
Black Women Less Likely to Get Sentinel Lymph Node Biopsy and More Likely to Have Lymphedema on Axillary Lymph Node Dissection
Although sentinel lymph node biopsy is the recommended method for axillary staging of node-negative breast cancer, racial disparities in access to care were found in a study presented at the 2012 San Antonio Breast Cancer Symposium. Black women were 12% less likely than white women with breast...
Role of Sentinel Node Surgery Explored in Node-positive Breast Cancer
Sentinel lymph node surgery performed after neoadjuvant chemotherapy in women presenting with node-positive disease could spare many patients with breast cancer needless axillary lymph node dissection, according to a study of the American College of Surgeons Oncology Group presented at the 2012 San ...
21-gene Recurrence Score Does Not Predict Paclitaxel Benefit
The 21-gene recurrence score significantly predicted the risk of recurrence and death in node-positive, estrogen receptor–positive patients treated with adjuvant chemoendocrine therapy, but it did not predict benefit from the addition of paclitaxel to the regimen in a subset of patients from the...
Subsets of Young Patients Have Higher Pathologic Complete Response Rates
In achieving a pathologic complete response to neoadjuvant chemotherapy, it seems that age matters, according to a study reported at the 2012 San Antonio Breast Cancer Symposium.1 Patients with breast cancer aged 35 and younger were more likely to achieve a pathologic complete response than their...
Oncogenic Pathway Signatures May Guide Treatment after Colorectal Cancer Resection
Deregulation of oncogenic signaling pathways was used to molecularly subclassify colorectal cancers into clinically relevant subgroups with both prognostic and predictive implications, in a study from the Duke Institute for Genome Sciences and Policy in Durham, North Carolina.1 “There is a need to...
Evaluating HER2 Status in Esophageal Cancers: FISH vs Immunohistochemistry
In screening patients with esophageal cancers for HER2 status, the relative efficiency of immunohistochemistry (IHC) vs fluorescence in situ hybridization (FISH) has been debated. Researchers from the Mayo Clinic compared the testing strategies and have proposed an algorithm that puts IHC up front, ...
The Pancreatic Cancer Action Network Welcomes New Members to Its Medical Advisory Board
The Pancreatic Cancer Action Network has named four new members to the organization’s Medical Advisory Board. The newest advisors are leading clinicians in the field of pancreatic cancer: Joseph M. Herman, MD, MSc, Johns Hopkins University; George A. Fisher Jr, MD, PhD, Stanford University; James...
Finding New Strategies to More Effectively Treat Pancreatic Cancer
While some progress has been made in understanding the molecular pathogenesis, genetic risk factors, and genomics of pancreatic adenocarcinoma, the disease remains one of the most challenging malignancies. According to Surveillance, Epidemiology, and End Results (SEER) figures, 44,000 people were...
Connecting to Conquer Cancer
One of the strengths of the Conquer Cancer Foundation of the American Society of Clinical Oncology is our relationships with others who want to join us in creating a world free from the fear of cancer. Our ability to do meaningful work is made possible by the individuals and organizations that...
ASCO International Expands to Improve Cancer Care Worldwide
As a global community of cancer care providers in more than 100 countries around the world, ASCO is uniquely positioned to improve cancer patient outcomes worldwide—an opportunity that it has seized since the organization’s inception through numerous innovative programs. Building upon this...
No Benefit of Adding Carboplatin to Pemetrexed in Second-line Treatment of Patients With Advanced Non–Small Cell Lung Cancer
An Italian randomized phase II study (GOIRC 02-2006 study) recently reported in Journal of Clinical Oncology by Andrea Ardizzoni, MD, of Azienda Ospedaliero-Universitaria in Parma, Italy, and colleagues showed no progression-free survival benefit of adding carboplatin to pemetrexed (Alimta) in...
SIDEBAR: Value-based Effective Care
The study by Chen and colleagues addresses the extremely important topic of the use and delivery schedule for radiotherapy in palliation for patients with metastatic lung cancer. The number of patients who will be considered candidates for such therapy in the United States and around the world each ...
